A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

Trial Profile

A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs AVB 620 (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Avelas BioSciences
  • Most Recent Events

    • 08 Dec 2016 Results published in an Avelas BioSciences media release.
    • 08 Dec 2016 According to an Avelas BioSciences media release, data from the study has been presented at the San Antonio Breast Cancer Symposium.
    • 08 Dec 2016 Status changed from active, no longer recruiting to completed, according to an Avelas BioSciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top